United States - English - NLM (National Library of Medicine)

clinimmune labs, university of colorado blood bank - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 30 ml - hpc (hematopoietic progenitor cells), cord blood is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. hpc, cord blood is contraindicated in patients with known hypersensitivity to dimethyl sulfoxide (dmso), dextran 40 or plasma proteins. [see description (11) and dosage and administration (2.2)] pregnancy category c. animal reproduction studies have not been conducted with hpc, cord

United States - English - NLM (National Library of Medicine)

university of texas md anderson cancer center - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - hematopoietic progenitor cell (hpc), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the benefit-risk assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. risk summary there are no data with hpc, cord blood use in pregnant women to inform a product-associated risk.  animal reproduction studies have not been conducted with hpc, cord blood. in the u.s. general population, the estimated background risk of major birth defects and misc

Israel - English - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; gentamicin as sulfate - ointment - betamethasone as dipropionate 0.5 mg / 1 g; gentamicin as sulfate 1 mg / 1 g - topical treatment of dermatosis complicated by secondary infection caused by organisms sensitive to gentamicin

Israel - English - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; gentamicin (as sulfate) - cream - gentamicin (as sulfate) 1 mg/g; betamethasone as dipropionate 0.5 mg/g - corticosteroids, potent, combinations with antibiotics - for the relief of the inflammatory manifestations of corticosteroid-responsive dermatoses when complicated by secondary infections caused by organisms susceptible to gentamycin.

United States - English - NLM (National Library of Medicine)

ssm cardinal glennon children's medical center st. louis cord blood bank - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 35 ml - allocord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none pregnancy category c. animal reproduction studies have not been conducted with allocord. it is also not known whether allocord can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st

United States - English - NLM (National Library of Medicine)

new york blood center - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 25 ml - hemacord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none pregnancy category c. animal reproduction studies have not been conducted with hemacord. it is also not known whether hemacord can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st

United States - English - NLM (National Library of Medicine)

lifesouth community blood centers, inc. - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 25 ml - cordcyte, hpc (hematopoietic progenitor cell), cord blood is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. pregnancy category c. animal reproduction studies have not been conducted with cordcyte. it is also not known whether cordcyte can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st

United States - English - NLM (National Library of Medicine)

duke university school of medicine, carolinas cord blood bank - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 900000000 in 25 ml - ducord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. risk summary there are no data with ducord use in pregnant women to inform a product-associated risk. animal reproduction studies have not been conducted with ducord. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in

United States - English - NLM (National Library of Medicine)

cleveland cord blood center - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 25 ml - clevecord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. risk summary there are no data with clevecord use in pregnant women to inform a product-associated risk.  animal reproduction studies have not been conducted with clevecord. in the u.s. general population, the estimated background risk of major birth defects and misca

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

organon south africa (pty) ltd - cream - see ingredients - 1 g betamethasone dipropionate 0,64 mg gentamicin sulphate 1 mg